But Nexavar is still used in RCC despite being clearly inferior to Sutent.
Nexavar sales are currently around $1B/yr, although I'm not sure of the split between RCC and HCC and other indications. So a drug that is superior to Nexavar and has a similar S/E profile is likely to be at least a reasonable commercial success.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.